How Close Are CRISPR, Gene Therapies to Lung Disease Breakthroughs?

March 16, 2022
Kevin Kunzmann

ChristianaCare’s Gene Editing Institute experts join the podcast to discuss the latest developments in gene editing.

Gene editing and CRISPR technology for curative disease treatment has been a long hoped-for advancement in medicine—but nonetheless is limited in clinician and patient understanding. If it were the future of medicine, just how far away is it still?

As of the March 2022 episode of Lungcast, it’s nearer than many think.

This newest episode of the American Lung Association (ALA) and HCPLive monthly podcast features a prospective and comprehensive review of gene therapy for pulmonary disease with a pair of leading scientists in the field.

Eric Kmiec, PhD, and Natalia Rivera-Torres, PhD, of the Christiana Care Gene Editing Institute, join host Albert Rizzo, MD, chief medical officer of the ALA, discuss their years-long work into targeted gene editing, and their breakthroughs in treatment capability for a variety of chronic diseases and cancers.

They also review how specific CRISPR technologies may address specific respiratory diseases burdening patients in the future.

Lungcast is a monthly respiratory health podcast series from the ALA produced by HCPLive.

Subscribe or listen to Lungcast on your favorite platforms:


x